$19.69
Arrowhead Pharmaceuticals is a biotechnology business based in the US. Arrowhead Pharmaceuticals shares (ARWR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $21.18 – an increase of 9.4% over the previous week. Arrowhead Pharmaceuticals employs 525 staff and has a trailing 12-month revenue of around $19.6 million.
What's in this guide?
- ARWR shares summary
- Compare share dealing platforms
- Is ARWR stock a buy or sell?
- Stock performance over time
- Can I short ARWR shares?
- Arrowhead Pharmaceuticals's financials
- How volatile are ARWR shares?
- Does Arrowhead Pharmaceuticals pay a dividend?
- Have ARWR shares ever split?
- Other common questions
Our top picks for where to buy Arrowhead Pharmaceuticals stock
- Earn 4.5% interest on uninvested cash with Gold
- Get up to $50,000 in instant deposits with Gold
- Easy, user-friendly trading
- Unlimited bonus amounts Oct 16-27
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Arrowhead Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ARWR. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Arrowhead Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Arrowhead Pharmaceuticals stock price (NASDAQ: ARWR)
Use our graph to track the performance of ARWR stocks over time.Arrowhead Pharmaceuticals shares at a glance
Latest market close | $21.18 |
---|---|
52-week range | $17.05 - $39.83 |
50-day moving average | $21.72 |
200-day moving average | $26.54 |
Wall St. target price | $47.29 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-4.65 |
Is it a good time to buy Arrowhead Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Arrowhead Pharmaceuticals price performance over time
Historical closes compared with the close of $21.18 from 2024-10-18
1 week (2024-10-11) | 14.86% |
---|---|
1 month (2024-09-20) | 1.83% |
3 months (2024-07-19) | -25.16% |
6 months (2024-04-19) | -5.15% |
1 year (2023-10-20) | -16.75% |
---|---|
2 years (2022-10-21) | -36.57% |
3 years (2021-10-18) | 66.14 |
5 years (2019-10-21) | 36.5 |
Arrowhead Pharmaceuticals financials
Revenue TTM | $19.6 million |
---|---|
Gross profit TTM | $240.7 million |
Return on assets TTM | -40.72% |
Return on equity TTM | -151.84% |
Profit margin | 0% |
Book value | $2.66 |
Market Capitalization | $2.5 billion |
TTM: trailing 12 months
Arrowhead Pharmaceuticals share dividends
We're not expecting Arrowhead Pharmaceuticals to pay a dividend over the next 12 months.
Have Arrowhead Pharmaceuticals's shares ever split?
Arrowhead Pharmaceuticals's shares were split on a 1:10 basis on 16 November 2011 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arrowhead Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arrowhead Pharmaceuticals shares which in turn could have impacted Arrowhead Pharmaceuticals's share price.
Arrowhead Pharmaceuticals share price volatility
Over the last 12 months, Arrowhead Pharmaceuticals's shares have ranged in value from as little as $17.05 up to $39.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arrowhead Pharmaceuticals's is 0.955. This would suggest that Arrowhead Pharmaceuticals's shares are less volatile than average (for this exchange).
Arrowhead Pharmaceuticals overview
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.
Frequently asked questions
nullWhat percentage of Arrowhead Pharmaceuticals is owned by insiders or institutions?
Currently 4.466% of Arrowhead Pharmaceuticals shares are held by insiders and 80.291% by institutions. How many people work for Arrowhead Pharmaceuticals?
Latest data suggests 525 work at Arrowhead Pharmaceuticals. When does the fiscal year end for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals's fiscal year ends in September. Where is Arrowhead Pharmaceuticals based?
Arrowhead Pharmaceuticals's address is: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 What is Arrowhead Pharmaceuticals's ISIN number?
Arrowhead Pharmaceuticals's international securities identification number is: US04280A1007 What is Arrowhead Pharmaceuticals's CUSIP number?
Arrowhead Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 042797100
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
Public.com Review 2024: No-Fee Options, With Rebates
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question